A5047472326- Veterinary Oncology Research
- Virus-based gene therapy research
- Infectious Diseases and Mycology
- Cancer Research and Treatments
- Sarcoma Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Oral and Maxillofacial Pathology
- Angiogenesis and VEGF in Cancer
- Microbial infections and disease research
- Salivary Gland Tumors Diagnosis and Treatment
- Glycosylation and Glycoproteins Research
- Peptidase Inhibition and Analysis
- Cancer, Hypoxia, and Metabolism
- Head and Neck Surgical Oncology
- Cancer therapeutics and mechanisms
- Mast cells and histamine
- Cancer Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Hedgehog Signaling Pathway Studies
- Neuroblastoma Research and Treatments
- Diet and metabolism studies
- Neuroendocrine Tumor Research Advances
- Ear and Head Tumors
- Gastrointestinal Tumor Research and Treatment
- Cancer Genomics and Diagnostics
University of Wisconsin–Madison
2016-2025
University of Wisconsin Carbone Cancer Center
2014-2024
John Wiley & Sons (United States)
2019-2020
Hudson Institute
2020
Purdue University West Lafayette
1994-2018
Colorado State University
1994-2015
Tufts University
1991-2015
Chesapeake Urology Associates
2015
North Carolina State University
2015
Swedish University of Agricultural Sciences
2015
In veterinary medical oncology, there is currently no standardized protocol for assessing response to therapy in solid tumours. The lack of such a formalized guideline makes it challenging critically compare outcome measures across various treatment protocols. Veterinary Cooperative Oncology Group (VCOG) membership consensus document presented here based on the recommendations subcommittee American College Internal Medicine (ACVIM) board-certified oncologists. This paper has used human...
The updated VCOG-CTCAE v2 guidelines contain several important updates and additions since the last update (v1.1) was released in 2011 published within Veterinary Comparative Oncology 2016. As Cooperative Group (VCOG) is no longer an active entity, original authors contributors to v1.0 v1.1 were consulted for input, additional co-authors sought expansion refinement of adverse event (AE) categories. includes expanded neurology, cardiac immunologic AE sections, addition procedural-specific...
Low-dose targeted radionuclide therapy combined with immune checkpoint inhibition enhances complete response rates in preclinical tumor models.
The purpose of this study was to evaluate the efficacy and toxicity an intensified dose protocol with no maintenance phase for treatment canine lymphoma. Forty-nine dogs all weighing more than 15 kg were entered. Dogs staged treated a modified version University Wisconsin (UW)-Madison Modifications included increased dosages cyclophosphamide (250 mg/m2 compared 200 mg/m2) doxorubicin (37.5 30 mg/m2), crossover chlorambucil or methotrexate. After 25 weeks on (17 treatments), therapy...
The purpose of this study was to compare a maintenance‐free chemotherapy protocol based on CHOP (H from hydroxydaunorubicin = doxorubicin, O Oncovin®= vincristine) similar with maintenance phase for the treatment canine lymphoma. Fifty‐three dogs multicentric lymphoma were treated 6‐month modified version University Wisconsin (UW)‐Madison (UW‐25). Disease‐free interval (DFI) and survival compared historical control group 55 prolonged phase. Remission rate 94.2% (complete remission 92.3%,...
Standardized assessment of response to therapy for lymphoma in dogs is lacking, making critical comparisons treatment protocols difficult. This Veterinary Cooperative Oncology Group (VCOG) consensus document, based on the recommendations a subcommittee ACVIM board-certified veterinary oncologists, was unanimously adopted at 29th Annual Conference Cancer Society (VCS) by VCOG membership. It has integrated guidance from criteria established human patients using standards available routine...
Paraffin-embedded, formalin-fixed tissue samples from 145 cats with lymphoma were analyzed for cluster of differentiation 3 (CD3, a surface antigen) immunoreactivity, argyrophilic nucleolar organizer region (AgNOR) frequency, and proliferating cell nuclear antigen labeling index (PCNA-LI). This information along signalment, anatomic site, feline leukemia virus (FeLV) status was used to determine the potential these indicators predict response therapy, remission, survival times, characterize...
The purpose of this study was to provide an initial assessment the potential biologic activity toceranib phosphate (Palladia®, Pfizer Animal Health, Madison, NJ, USA) in select solid tumours dogs. Cases which used treat dogs with apocrine gland anal sac adenocarcinoma (AGASACA), metastatic osteosarcoma (OSA), thyroid carcinoma, head and neck carcinoma nasal were included. Clinical benefit (CB) observed 63/85 (74%) including 28/32 AGASACA [8 partial response (PR), 20 stable disease (SD)],...
To evaluate time to first recurrence (TFR) and overall survival in cats with presumed vaccine-associated sarcomas (VAS) treated excision.Retrospective study.61 VAS.Medical records of that received excision as the only initial treatment for VAS were reviewed prognosis. Overall curves TFR determined.Median was 94 days. Median tumors performed at a referral institution (274 days) significantly longer than excised by referring veterinarian (66 days). Radical yielded median (325 did marginal (79...
Seventy‐one dogs with histologically confirmed appendicular osteosarcoma were evaluated. Seventeen treated amputation and two received postoperative doses of IV cisplatin given 21 days apart (group 1). Nineteen before amputation, a second dose immediately after 2). Thirty‐five by the affected limb no chemotherapy 3). The median disease‐free interval for group 1 was 226 days, 177 2. This not significantly different. survival time 262 1, 282 2 119 3. Group had times that longer than in Two...
Abstract Purpose: Genetically modified bacteria are a potentially powerful anticancer therapy due to their tumor targeting capacity, inherent antitumor activity, and ability serve as efficient vectors for gene delivery. This study sought characterize the acute short-term toxicities colonization rates of genetically Salmonella typhimurium (VNP20009) in dogs with spontaneous tumors, context phase I dose escalation trial. Experimental Design: Forty-one pet variety malignant tumors received...
The medical records of 61 dogs with MCT at high risk for metastasis that were treated prednisone and VBL following excision +/- radiation therapy reviewed, median disease-free interval (DFI), overall survival time (OS) prognostic factors assessed. Adverse effects, mostly mild, noted in 26% patients, usually after the first dose. 6.5% experienced severe neutropenia. DFI was 1305 days, OS not reached, 65% alive 3 years. 100% "high-risk" grade II III 1374 days. Histologic grade, location...
Forty-one dogs with mast cell tumors (MCTs) were treated oral prednisone and injectable vinblastine (VBL), both in the adjuvant setting (23 dogs) gross disease (18 dogs). Adverse effects noted 20% (8/41) of patients, usually after 1st dose VBL. considered mild 6, severe, necessitating treatment discontinuation, 2 (5%). Overall response rate evaluable was 47% (7/15), consisting 5 complete responses partial responses. Median duration 154 days (24 to >645 days). As therapy incomplete surgical...
Survival following amputation and administration of single-agent carboplatin for treatment appendicular osteosarcoma (OSA) in dogs was retrospectively examined. Records 155 with OSA treated were included from 14 centers. Any dosage, number doses, protocol schedule eligible inclusion. The median disease-free interval (DFI) 256 days. overall survival time 307 Similar prognostic factors identified this study as reported prior studies canine OSA. Median DFI comparable to those the original...